An intravenous BCMA x CD3 bispecific T-cell–engaging antibody that binds BCMA (TNFRSF17) on multiple myeloma plasma cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect T cells to lyse BCMA-positive tumor cells via perforin/granzyme release and cytokine-driven cytotoxicity.
Intravenous BCMA×CD3 bispecific antibody that binds BCMA on multiple myeloma cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect T cells to kill BCMA-positive tumor cells via perforin/granzyme release and cytokine-mediated cytotoxicity.
YES
DIRECT
The BCMA×CD3 bispecific bridges T cells to BCMA+ cells, activating TCR/CD3 and inducing perforin/granzyme-mediated cytolysis and cytokine-driven killing of the BCMA-expressing cells.
An intravenous BCMA x CD3 bispecific T-cell–engaging antibody that binds BCMA (TNFRSF17) on multiple myeloma plasma cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect T cells to lyse BCMA-positive tumor cells via perforin/granzyme release and cytokine-driven cytotoxicity.
Intravenous BCMA×CD3 bispecific antibody that binds BCMA on multiple myeloma cells and CD3 on T cells to form an immune synapse, activate TCR/CD3 signaling, and redirect T cells to kill BCMA-positive tumor cells via perforin/granzyme release and cytokine-mediated cytotoxicity.
NO
INDIRECT
The bispecific binds CD3 on T cells and BCMA on myeloma cells to form an immune synapse, activating T cells to release perforin/granzymes and cytokines that kill BCMA+ tumor cells; CD3+ T cells are not killed.
Humanized IgG1 monoclonal antibody targeting CD38 on myeloma cells, mediating ADCC, CDC, ADCP, and direct pro-apoptotic and immune-modulating effects.
Humanized IgG1 monoclonal antibody targeting CD38 on myeloma cells; mediates antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP), and can induce direct pro-apoptotic and immune-modulating effects, leading to lysis of CD38-expressing tumor cells.
YES
DIRECT
Isatuximab binds CD38 on target cells and recruits immune effectors via its Fc to mediate ADCC, CDC, and ADCP; it can also trigger direct pro‑apoptotic signaling, leading to lysis of CD38-expressing cells.
Humanized IgG1 anti-CD20 monoclonal antibody that selectively depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing B‑cell antigen presentation, proinflammatory cytokines, and autoantibody production to dampen B–T cell interactions and CNS inflammation in MS. Also known as RO4964913.
Humanized IgG1 anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ B cells via ADCC, complement-dependent cytotoxicity, and apoptosis; reduces B-cell antigen presentation, cytokine and autoantibody production, dampening B–T cell interactions and neuroinflammation.
YES
DIRECT
Ocrelizumab binds CD20 on B cells and triggers Fc-mediated ADCC/phagocytosis by immune effectors and complement-dependent cytotoxicity; it can also induce apoptosis, leading to depletion of CD20+ cells.